SOST and type 2 diabetes mellitus: Despite the wide confidence interval (including the null), their direction of effect suggests increased triglycerides and apolipoprotein B, and reduced levels of protective HDL and apolipoprotein A. Similarly, they found a higher risk of type 2 diabetes mellitus among UK Biobank participants with lower predicted levels of sclerostin.